In the past week, SNY stock has gone down by -4.13%, with a monthly decline of -10.42% and a quarterly plunge of -12.95%. The volatility ratio for the week is 2.07%, and the volatility levels for the last 30 days are 1.73% for Sanofi ADR The simple moving average for the last 20 days is -6.64% for SNY’s stock, with a simple moving average of -5.46% for the last 200 days.
Is It Worth Investing in Sanofi ADR (NASDAQ: SNY) Right Now?
The price-to-earnings ratio for Sanofi ADR (NASDAQ: SNY) is 26.50x, which is above its average ratio. Moreover, the 36-month beta value for SNY is 0.57. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SNY is 2.51B and currently, short sellers hold a 0.32% of that float. On November 19, 2024, SNY’s average trading volume was 1.84M shares.
SNY) stock’s latest price update
Sanofi ADR (NASDAQ: SNY) has experienced a decline in its stock price by -0.91 compared to its previous closing price of 48.51. However, the company has seen a fall of -4.13% in its stock price over the last five trading days. zacks.com reported 2024-11-18 that The FDA is set to give its decision on SNY and REGN’s sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Analysts’ Opinion of SNY
Many brokerage firms have already submitted their reports for SNY stocks, with Argus repeating the rating for SNY by listing it as a “Buy.” The predicted price for SNY in the upcoming period, according to Argus is $60 based on the research report published on July 26, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see SNY reach a price target of $55. The rating they have provided for SNY stocks is “Equal-Weight” according to the report published on January 23rd, 2024.
SNY Trading at -11.39% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.48% of loss for the given period.
Volatility was left at 1.73%, however, over the last 30 days, the volatility rate increased by 2.07%, as shares sank -9.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.13% lower at present.
During the last 5 trading sessions, SNY fell by -3.93%, which changed the moving average for the period of 200-days by +2.60% in comparison to the 20-day moving average, which settled at $51.50. In addition, Sanofi ADR saw -3.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.61 for the gross margin
The net margin for Sanofi ADR stands at 0.12. The total capital return value is set at 0.11. Equity return is now at value 5.80, with 3.31 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is 13.78.
Currently, EBITDA for the company is 12.6 billion with net debt to EBITDA at 1.68. When we switch over and look at the enterprise to sales, we see a ratio of 2.2. The receivables turnover for the company is 7.0for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.00.
Conclusion
To wrap up, the performance of Sanofi ADR (SNY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
